Skip to main content
    E

    Editas Medicine Inc (EDIT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.82
    -0.04 (-2.41%)

    Market Cap: $334.92M

    Last updated: Nov 17, 2026 at 4:26 PM ET

    Editas Medicine Inc (EDIT) Stock Chart

    Updated Nov 17, 2026. Prices from end-of-day market data; valuation figures from company filings.

    Editas Medicine (EDIT) has a latest price of $1.82 on Nov 17, 2026, 53.7% below its 52-week high of $3.94. Its price fell 29.8% over the past 12 months. The month-end price fell 81.1% over the 10 years through Oct 2026, a compound annual decline of 15.4%.

    Price Chart

    From Oct 2016 to Oct 2026, its highest month-end close was $70.11 in Dec 2020 and its lowest $1.16 in Mar 2025, adjusted for splits.

    Month-end closes, adjusted for splits. Dividends are not included.

    Chart EDIT with Advanced Charting

    Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for EDIT.

    Free with a GNG account. No credit card.

    Price Performance

    Over the past 3 months the price fell 43.8%, and over 6 months it fell 25.8%. The month-end price fell 60.0% over the 3 years through Oct 2026, a compound annual decline of 26.3%.

    PeriodChange
    1 month-24.6%
    3 months-43.8%
    6 months-25.8%
    12 months-29.8%
    12 months, with dividends-29.8%
    Price change over each period. Dividends are not included unless the row says so.
    PeriodChangePer year
    3 years-60.0%-26.3%
    5 years-92.7%-40.8%
    10 years-81.1%-15.4%
    From month-end closes through Oct 2026. Per year is the compound annual rate.

    Price by Year

    Its best calendar year was 2020, when the price rose 136.8%, and its weakest was 2024, when it fell 87.5%.

    YearCloseChange
    2026 through Oct 2026$2.67+30.2%
    2025$2.05+61.4%
    2024$1.27-87.5%
    2023$10.13+14.2%
    2022$8.87-66.6%
    2021$26.55-62.1%
    2020$70.11+136.8%
    2019$29.61+30.2%
    2018$22.75-26.0%
    2017$30.73+89.3%
    Each year ends at its December month-end close, adjusted for splits.

    Trading Range

    The price is 29.3% below its 50-day average of $2.58 and 32.4% below its 200-day average of $2.70.

    MeasureValuePrice vs
    Latest price (Nov 17, 2026)$1.82
    52-week high$3.94-53.7%
    52-week low$1.66+9.9%
    50-day average$2.58-29.3%
    200-day average$2.70-32.4%
    Moving averages of daily closes. The last column compares the price with each level.

    Price Risk

    Over 3 years, its largest fall from a peak was 91.2%.

    MeasureValue
    1-year beta2.36
    Largest fall, 1 year-51.3%
    Largest fall, 3 years-91.2%
    Beta against the S&P 500 over one year. A fall is measured from a peak to the low after it.

    Advanced Charting Features

    Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.

    • Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
    • Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
    • Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
    • Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.

    Frequently Asked Questions About EDIT

    What is EDIT's 1-year price change?

    Editas Medicine's price fell 29.8% over the past 12 months. With dividends included, the 12-month total return was -29.8%.

    What is EDIT's 5-year price change?

    Editas Medicine's month-end price fell 92.7% over the 5 years through Oct 2026, a compound annual decline of 40.8%. These figures leave out dividends.

    What is EDIT's 52-week high and low?

    Editas Medicine's 52-week high is $3.94 and its 52-week low is $1.66. Its latest price of $1.82 on Nov 17, 2026 is 53.7% below the high.

    What is EDIT's beta?

    Editas Medicine's 1-year beta against the S&P 500 is 2.36, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 51.3%.

    Is the EDIT chart free?

    Yes. Advanced Charting for EDIT is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.